Patara Pharma has announced the appointment of John Schmid to its Board of Directors. The company’s lead product, PA101B, is a potential  treatment for pulmonary fibrosis and moving through clinical trials. “John joins Patara’s board at a pivotal time as we advance our flagship program, PA101B, through multiple Phase 2 studies to improve…
Patara Pharma, Advancing an IPF Treatment in Clinical Tests, Names Finance Officer to Its Board
Idiopathic pulmonary fibrosis is a degenerative lung disease affecting the lives of thousands of people. It causes the scarring of the lungs, making it difficult to breathe, among other symptoms. The cause of it is still unknown and there isn’t much information about the disease. Usually, patients suffering from…
https://www.youtube.com/watch?v=lgAId_2G85w In this video from NewsKAYadams, let’s remember John Palmer, a veteran NBC News reporter who passed away due to complications from pulmonary fibrosis.  The 77-year-old former White House correspondent and Today show host died at George Washington Hospital after a brief illness. Palmer was a…
Scientists are constantly looking for new ways to make medicine more personalized. One way they are doing this is by researching stem cells. These researched cells are undifferentiated, which means they don’t have a specific job or function, so because of this they have the potential to become other kinds…
More effective treatment of idiopathic pulmonary fibrosis (IPF) is needed for reasons as solidly grounded in economics as they are in basic healthcare, a study published in the Journal of Managed Care & Specialty Pharmacy points out — showing that acute exacerbations and disease-related hospitalizations in lung fibrosis patients are associated with high…
Having a lung transplant may be an overwhelming experience. Your pulmonary fibrosis care team is there to help you every step of the way, but it is your body that will undergo the actual procedure. It’s of the utmost importance to have an…
Joe Nichols is a country singer and songwriting superstar, who lost his father to idiopathic pulmonary fibrosis — a rare and fatal lung disease that causes the scaring of the lungs. His father was misdiagnosed for years, a factor which led to his death. NewsWatch Television shares…
Having pulmonary fibrosis has an impact on many aspects of life. A person may not be able to do as much walking, climb stairs so well, or just becomes tired easily. However, one can still enjoy life and the pleasures of it, such as going…
Drugs targeting a pathway centered on a molecule named PI3K and a mammalian target of rapamycin (mTOR) — another molecule in the same pathway — are in early, preclinical tests in a variety of disease conditions, and recently completed a Phase 1 cancer trial. A study from University College London  also found that…
Professor Jürgen Behr, from the University of Munich, Germany, talks in this video by Boehringer Ingelheim Idiopathic Pulmonary Fibrosis about idiopathic pulmonary fibrosis and how patients can benefit from receiving medical treatment for IPF. Learn more about pulmonary fibrosis: https://bit.ly/1VElTQA…
